TONIX Pharmaceuticals to Present at the OneMedForum San Francisco 2011 on January 11 and at the Biotech Showcase™ on Janua

NEW YORK--(BUSINESS WIRE)-- TONIX Pharmaceuticals (formerly known as Krele Pharmaceuticals), a specialty pharmaceutical company focused on central nervous system (CNS) disorders, announced today the Company will present at the OneMedForum San Francisco 2011 at 10:15 am PT on January 11, 2011, at the Sir Francis Drake Hotel in San Francisco. TONIX also will present at the Biotech Showcase™, co-produced by Demy-Colton Life Science Advisors and the EBD Group, at 3:45 pm PT on January 12, 2011, at the Parc 55 Wyndham San Francisco Hotel. TONIX President Seth Lederman, M.D., will provide an update on the Company’s R&D programs, including its lead clinical-stage program in fibromyalgia syndrome.

About TONIX Pharmaceuticals

TONIX Pharmaceuticals is developing new treatments for challenging disorders of the central nervous system. The Company’s most advanced program targets fibromyalgia syndrome based on very low dosage cyclobenzaprine, an active pharmaceutical ingredient used in higher doses in approved therapeutics in the U.S. Based on this foundation, the Company is building a deep and diverse pipeline of high-value medications for other syndromes, disorders and diseases, including post-traumatic stress disorder. For more information, please visit www.tonixpharma.com.



CONTACT:

TONIX Pharmaceuticals
Susan Oliver, 212-980-9155 ext. 104
[email protected]
or
For Media:
Burns McClellan on behalf of TONIX
Justin Jackson, 212-213-0006
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Research  Science

MEDIA:

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.